Blocking NAMPT with FK866 Eases Liver Fibrosis in Mice, Challenging the NAD+ Boosting Narrative
In mice with chemically induced liver scarring, the NAMPT inhibitor FK866 lowered liver injury, fibrosis markers, and inflammation, pointing to a new target.
Résumé
Liver fibrosis, the scarring that drives chronic liver disease, has no approved therapy that reliably halts or reverses it. Researchers tested FK866, a drug that inhibits NAMPT (a key enzyme in NAD+ production), in mice with fibrosis induced by diethylnitrosamine (DEN). Fibrotic livers showed higher NAMPT and PARP1 levels. Treatment with FK866 reduced liver enzymes ALT and AST, improved liver tissue structure, and lowered fibrosis markers including fibronectin, collagen IV, laminin, and α-smooth muscle actin. It also reduced NAD+ levels, PARP1, and inflammatory signals such as IL-1β, IL-6, TNF-α, and P65 (NF-κB). The findings suggest that the NAMPT–PARP1–inflammation axis contributes to liver fibrosis and may be a therapeutic target. This is a preclinical mouse study, and results do not yet support use in people or any change in NAD+ supplement practice.
Résumé détaillé
Chronic liver disease is a major global health burden, and fibrosis is the central process that leads toward cirrhosis and liver failure. Despite decades of research, treatments that halt or reverse fibrosis remain limited, so new molecular targets are needed.
This study examined NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway, and its inhibitor FK866. Mice were given diethylnitrosamine (DEN) to induce liver fibrosis, and the researchers measured hepatic NAMPT and PARP1 expression, blood liver enzymes, tissue pathology, fibrosis markers, NAD+ levels, and inflammatory proteins.
DEN-induced fibrosis was accompanied by higher hepatic NAMPT and PARP1. FK866 treatment blunted the rise in ALT and AST, reversed histological damage, and suppressed fibronectin, collagen IV, laminin, and α-SMA, a marker of activated hepatic stellate cells. Mechanistically, FK866 lowered NAD+, NAMPT, and PARP1 protein, along with IL-1β, IL-6, TNF-α, and P65, suggesting reduced NF-κB-linked inflammation.
The results suggest that, in this model, excess NAMPT/NAD+/PARP1 signaling promotes inflammation and scarring, and that dampening it may protect the liver. This is notable for the longevity field, where NAD+ boosting is popular. It implies that the effect of NAD+ modulation is likely context-dependent, and that raising NAD+ may not be beneficial in every tissue or disease state.
Caveats are important. Only the abstract was available, so details such as dosing, group sizes, timing, and statistics could not be assessed. DEN is a carcinogen-based model that may not mirror human fibrosis from fatty liver, alcohol, or viral hepatitis. NAMPT inhibitors have shown toxicity in clinical settings, and no human data are presented.
Principales conclusions
- DEN-induced liver fibrosis in mice coincided with increased hepatic NAMPT and PARP1 expression.
- FK866 reduced the elevations in ALT and AST, markers of liver injury.
- FK866 reversed histopathological changes and lowered fibronectin, collagen IV, laminin, and α-SMA.
- Treatment decreased NAD+, NAMPT, and PARP1 protein levels in fibrotic liver.
- FK866 suppressed IL-1β, IL-6, TNF-α, and P65, indicating reduced inflammatory signaling.
Méthodologie
Preclinical in vivo study using a diethylnitrosamine (DEN)-induced liver fibrosis mouse model. Researchers compared FK866-treated and untreated mice using serum enzymes, histopathology, fibrosis markers, NAD+ levels, and protein expression of NAMPT, PARP1, and inflammatory mediators.
Limites de l'étude
Findings come from a single mouse chemical-injury model, with no human data, and only the abstract was reviewed, limiting assessment of dose, sample size, and statistics. Causality of the NAD+/PARP1 mechanism is inferred from expression changes, and NAMPT inhibitors carry known toxicity concerns that may hinder translation.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :